Betnesol-N (betamethasone + neomycin): Uses, Dosage & Side Effects

What it's for (Indications)

Betamethasone + Neomycin, exemplified by Rekabson-N, is a potent topical corticosteroid combined with an aminoglycoside antibiotic, primarily indicated for the treatment of inflammatory skin conditions that are either complicated by a secondary bacterial infection or where there is a significant risk of such an infection.
This therapeutic combination is particularly effective for dermatoses responsive to corticosteroids, such as eczema (atopic, discoid, stasis), psoriasis (excluding widespread plaque psoriasis), allergic dermatitis, neurodermatitis, and contact dermatitis, where susceptible bacterial pathogens are present.
The corticosteroid component, betamethasone, provides anti-inflammatory, antipruritic, and vasoconstrictive effects, while neomycin targets and eradicates susceptible bacterial microorganisms.
Its use is generally recommended for short-term application, typically not exceeding 7 to 14 days, to manage acute exacerbations and mitigate the risks associated with prolonged corticosteroid and antibiotic exposure.
Prior to initiation, identifying the bacterial pathogen and its susceptibility to neomycin is advisable to ensure optimal therapeutic outcomes and prevent the development of antibiotic resistance.

Dosage Information

Type	Guideline
Standard	This medication is intended for topical application only. A thin layer of the cream or ointment should be gently applied to the affected skin area(s) usually once or twice daily, or as directed by a healthcare professional. The precise frequency and duration of treatment should be determined based on the severity and extent of the dermatosis, as well as the patient's response to therapy. Treatment duration should be kept as short as possible, generally not exceeding 7 to 14 days, to minimize the risk of adverse effects, including HPA axis suppression and the development of antibiotic resistance. Occlusive dressings should typically be avoided unless specifically instructed by a physician, as they can significantly enhance systemic absorption of the corticosteroid, increasing the potential for adverse systemic effects. For pediatric patients, extreme caution is advised, and application should be limited to the smallest effective amount for the shortest possible duration due to their increased susceptibility to systemic corticosteroid effects and potential neomycin absorption.

Type

Guideline

Standard

This medication is intended for topical application only. A thin layer of the cream or ointment should be gently applied to the affected skin area(s) usually once or twice daily, or as directed by a healthcare professional. The precise frequency and duration of treatment should be determined based on the severity and extent of the dermatosis, as well as the patient's response to therapy. Treatment duration should be kept as short as possible, generally not exceeding 7 to 14 days, to minimize the risk of adverse effects, including HPA axis suppression and the development of antibiotic resistance. Occlusive dressings should typically be avoided unless specifically instructed by a physician, as they can significantly enhance systemic absorption of the corticosteroid, increasing the potential for adverse systemic effects. For pediatric patients, extreme caution is advised, and application should be limited to the smallest effective amount for the shortest possible duration due to their increased susceptibility to systemic corticosteroid effects and potential neomycin absorption.

Safety & Warnings

Common Side Effects

Topical application of betamethasone + neomycin can lead to various localized and, less commonly, systemic side effects.
Common local adverse reactions associated with the corticosteroid component include skin atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, and allergic contact dermatitis.
Prolonged or extensive use, especially under occlusion, can increase the risk of systemic absorption, potentially leading to hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria.
The neomycin component can cause localized hypersensitivity reactions, manifesting as rash, itching, or worsening of the underlying skin condition.
Although rare with topical use, significant systemic absorption of neomycin, particularly when applied to large areas of denuded or compromised skin, can potentially lead to ototoxicity (hearing impairment or labyrinthine damage) and nephrotoxicity (kidney damage), especially in patients with pre-existing renal impairment or those concurrently receiving other ototoxic/nephrotoxic medications.
Secondary infections (fungal or viral) may also occur, particularly if the initial infection is misdiagnosed or resistance develops.

Serious Warnings

Black Box Warning: While there is no formal FDA Black Box Warning specifically designated for topical Betamethasone + Neomycin, clinicians and patients must be fully aware of several serious potential adverse effects, particularly with prolonged use, application to large surface areas, or on denuded skin. The significant systemic absorption of corticosteroids can lead to hypothalamic-pituitary-adrenal (HPA) axis suppression, potentially causing adrenal insufficiency upon withdrawal, Cushing's syndrome, and growth retardation in pediatric patients. Furthermore, systemic absorption of neomycin, though uncommon with appropriate topical use, carries a serious risk of ototoxicity (irreversible hearing loss) and nephrotoxicity, especially in individuals with compromised renal function, when applied to extensive areas of damaged skin, or when co-administered with other ototoxic or nephrotoxic medications. Hypersensitivity reactions to neomycin are also common and can manifest as worsening of the skin condition, necessitating immediate discontinuation. Patients should be closely monitored for signs of these serious adverse effects, and the medication's use should be strictly limited in duration and extent of application to mitigate these risks. Avoid ophthalmic use. This medication is not to be used for prolonged periods or indiscriminately due to the potential for severe, irreversible consequences.
The use of betamethasone + neomycin requires careful consideration due to potential systemic absorption of both components.
Prolonged application, use on large surface areas, occlusive dressings, and application to broken or denuded skin can significantly increase systemic absorption of betamethasone, leading to HPA axis suppression, Cushing's syndrome, hyperglycemia, and potential growth retardation in children.
Similarly, systemic absorption of neomycin, particularly under these conditions or in individuals with impaired renal function, carries a risk of ototoxicity (irreversible hearing loss) and nephrotoxicity.
Patients should be monitored for signs of systemic toxicity, and treatment should be discontinued if such effects occur.
Hypersensitivity reactions to neomycin are relatively common and may manifest as a worsening of the skin condition or a failure to heal; if suspected, the medication should be stopped.
This combination is not indicated for primary bacterial infections without an inflammatory component, nor for fungal, viral (e.
g.
, herpes simplex, varicella), or parasitic skin infections.
Avoid contact with eyes and mucous membranes.
Prolonged use of topical antibiotics may lead to the overgrowth of non-susceptible organisms, including fungi, and can foster the development of bacterial resistance.
The medication should not be used in the presence of a perforated eardrum if applied to the ear canal, nor on conditions like rosacea or perioral dermatitis, as corticosteroids can exacerbate these conditions.

How it Works (Mechanism of Action)

Betamethasone + Neomycin combines the therapeutic effects of a potent synthetic corticosteroid with a broad-spectrum aminoglycoside antibiotic. Betamethasone, a Group III (potent) corticosteroid, exerts its anti-inflammatory, antipruritic, and vasoconstrictive actions primarily by inducing the synthesis of phospholipase A2 inhibitory proteins, collectively known as lipocortins. These proteins effectively inhibit the release of arachidonic acid from cell membrane phospholipids, thereby suppressing the subsequent biosynthesis of potent mediators of inflammation, such as prostaglandins and leukotrienes. Additionally, betamethasone stabilizes lysosomal membranes, inhibits leukocyte and macrophage accumulation in inflamed areas, reduces leukocyte adhesion to the capillary endothelium, and decreases fibroblast proliferation and collagen deposition, ultimately reducing swelling, redness, and itching. Neomycin, the antibiotic component, acts by irreversibly binding to the 30S ribosomal subunit of susceptible bacteria. This binding interferes with protein synthesis, leading to misreading of the mRNA template and ultimately inhibiting the growth and multiplication of bacterial cells, resulting in a bactericidal effect against a range of Gram-negative and some Gram-positive bacteria.